HeartSciences (HSCS) Liabilities and Shareholders Equity (2022 - 2025)

HeartSciences (HSCS) has reported Liabilities and Shareholders Equity for 4 consecutive years, with $4.2 million the latest figure, recorded in Q4 2025.

• Quarterly Liabilities and Shareholders Equity changed N/A year-over-year to $4.2 million in Q4 2025, while the trailing twelve-month figure through Apr 2026 was $16.7 million (down 35.68% YoY) and the FY2025 annual result came in at $4.2 million, down 55.56% from the prior year.
• Liabilities and Shareholders Equity retreated to $4.2 million in Q4 2025 per HSCS's latest filing, from $6.0 million in the prior quarter.
• Over the last five years, Liabilities and Shareholders Equity for HSCS reached as high as $10.8 million in Q1 2024 and fell as low as $2.1 million in Q2 2022.
• A 4-year average of $5.4 million and a median of $5.2 million in 2022 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2024 — Liabilities and Shareholders Equity jumped 228.38% — and 2025, when it tumbled 55.56%.
• Year by year, Liabilities and Shareholders Equity stood at $4.8 million in 2022, then tumbled by 50.36% to $2.4 million in 2023, then soared by 228.38% to $7.8 million in 2024, then plunged by 45.7% to $4.2 million in 2025.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $4.2 million, $6.0 million, and $6.4 million for Q4 2025, Q4 2025, and Q3 2025 respectively.